Bioavailability of Oral BIRB 796 BS Tablets With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers

Inclusion Criteria: * Healthy male subjects as determined by results of screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age \>=18 and \<=55 years * Laboratory examinations within a clinically defined reference range * Helicobacter pylori negative * Able to tolerate pH probe application * Body mass index (BMI) \>=18.5 and \<=29.9 kg/m2 Exclusion Criteria: * Any finding of the medical examination (including blood pressure, pulse rate and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hormonal disorders * Surgery of gastrointestinal tract (excluding appendectomy) * History of orthostatic hypotension, fainting spells or blackouts * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator including study drugs * History of vasculitis (past history of fever, malaise, myalgias, rash, etc.) * Intake of drugs with a long half-life (\> 24 hours) within 1 month or 10 half lives of that drug, whichever is longer, prior to administration of study drugs or during the trial * Use of any drugs that might influence the results of the trial within 10 days prior to administration or during the trial * Use of grapefruit or grapefruit juice, alcohol, green tea, methylxanthine-containing products or tobacco within 5 days of study drug administration * Participation in another trial with an investigational drug within 1 month prior to administration or during the trial * Smoker * Alcohol abuse (\> 60 g/day) * Drug abuse * Blood or plasma donation (\>400 ml) within 1 month prior to administration or during trial * Excessive physical activities within 5 days prior to administration or during the trial * Following specific laboratory findings: aspartate aminotransferase, alanine transaminase, Gamma-glutamyl-transferase above the reference range * Inability to comply with dietary regimen of study centre * Inability to comply with investigator's instructions